Technical Data
Colchicine (NSC 757, EINECS 200-598-5)
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Anti-cancer compound. Microtubule assembly inhibitor. Depolymerizes microtubules and limits microtubule formation (inactivates spindle fibre formation). Inhibits mitosis during cell division at metaphase by inhibiting spindle formation. Anti-inflammatory compound. Suppresses monosodium urate crystal-induced NLRP3/NALP3 inflammasome-driven caspase-1 activation, IL-1beta processing and release, and L-selectin expression on neutrophils at micromolar concentrations. Blocks the release of a crystal-derived chemotactic factor from neutrophil lysosomes, blocks neutrophil adhesion to, and inhibits monosodium urate crystal-induced production of superoxide anions from neutrophils at nanomolar concentrations. Drug used in treatment of gout, familial Mediterranean fever, pericarditis and Behect's disease. Investigated for its anti-cancer activity. It has a narrow therapeutic index with no clear-cut distinction between nontoxic, toxic and lethal doses, causing substantial confusion among clinicians. Apoptosis inducer in a variety of normal and tumor cell lines.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Stable for at least 2 years after receipt when stored at -20C.

CAS Number:

Molecular Formula:

Molecular Weight:
Purity: >98% (HPLC)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
Interactions of colchicine with tubulin: S.B. Hastie; Pharmacol. Ther. 51, 377 (1991) (Review)
Analysis of the colchicine-binding site of beta-tubulin: R.G. Burns; FEBS Lett. 297, 205 (1992) (Review)
Colchicine induces apoptosis in cerebellar granule cells: E. Bonfoco, et al.; Exp. Cell. Res. 218, 189 (1995)
Sustained JNK activation induces endothelial apoptosis: studies with colchicine and shear stress: Y.L. Hu, et al.; Am. J. Physiol. 277, H1593 (1999)
Microtubules as a target for anticancer drugs: M.A. Jordan & L. Wilson; Nat. Rev. Cancer 4, 253 (2004)
Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin: B. Bhattacharyya, et al.; Med. Res. Rev. 28, 155 (2008) (Review)
Colchicine: its mechanism of action and efficacy in crystal-induced inflammation: G. Nuki; Curr. Rheumatol. Rep. 10, 218 (2008) (Review)
Colchicine poisoning: the dark side of an ancient drug: Y. Finkelstein, et al.; Clin. Toxicol. (Phila). 48, 407 (2010) (Review)
Colchicine for the treatment of gout: P. Richette & T. Bardin; Expert Opin. Pharmacother. 11, 2933 (2010) (Review)

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.